According to @StockMKTNewz, Eli Lilly said it plans to spend $6 billion to build a manufacturing plant in Huntsville, Alabama to help boost production of its experimental obesity pill, orforglipron, and other drugs, as reported by CNBC. According to @StockMKTNewz citing CNBC, the company directly linked the investment to increasing orforglipron supply, a trading-relevant signal for GLP-1 capacity tracking. According to @StockMKTNewz and CNBC, neither source referenced any direct cryptocurrency market impact from this development.